ES2656762T3 - Método y composiciones para tratamiento del cáncer - Google Patents

Método y composiciones para tratamiento del cáncer Download PDF

Info

Publication number
ES2656762T3
ES2656762T3 ES09723788.7T ES09723788T ES2656762T3 ES 2656762 T3 ES2656762 T3 ES 2656762T3 ES 09723788 T ES09723788 T ES 09723788T ES 2656762 T3 ES2656762 T3 ES 2656762T3
Authority
ES
Spain
Prior art keywords
compositions
cancer treatment
composition
effective amount
therapeutically effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09723788.7T
Other languages
English (en)
Spanish (es)
Inventor
Angelika Burger
Hans Hendriks
Bernardus Rademaker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KOMINOX Inc
Original Assignee
KOMINOX Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KOMINOX Inc filed Critical KOMINOX Inc
Application granted granted Critical
Publication of ES2656762T3 publication Critical patent/ES2656762T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES09723788.7T 2008-03-27 2009-03-24 Método y composiciones para tratamiento del cáncer Active ES2656762T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US3998708P 2008-03-27 2008-03-27
US39987P 2008-03-27
US408864 2009-03-23
US12/408,864 US20090246291A1 (en) 2008-03-27 2009-03-23 Method and compositions for treatment of cancer
PCT/US2009/038104 WO2009120697A2 (en) 2008-03-27 2009-03-24 Method and compositions for treatment of cancer

Publications (1)

Publication Number Publication Date
ES2656762T3 true ES2656762T3 (es) 2018-02-28

Family

ID=41114644

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09723788.7T Active ES2656762T3 (es) 2008-03-27 2009-03-24 Método y composiciones para tratamiento del cáncer

Country Status (20)

Country Link
US (2) US20090246291A1 (enExample)
EP (1) EP2268292B1 (enExample)
JP (2) JP5543956B2 (enExample)
KR (1) KR101634138B1 (enExample)
CN (2) CN102046187A (enExample)
AU (1) AU2009228378B2 (enExample)
BR (1) BRPI0909164A2 (enExample)
CA (1) CA2719766C (enExample)
CY (1) CY1120536T1 (enExample)
DK (1) DK2268292T3 (enExample)
ES (1) ES2656762T3 (enExample)
HU (1) HUE036609T2 (enExample)
LT (1) LT2268292T (enExample)
MX (1) MX2010010621A (enExample)
PL (1) PL2268292T3 (enExample)
PT (1) PT2268292T (enExample)
RU (1) RU2508116C2 (enExample)
SI (1) SI2268292T1 (enExample)
WO (1) WO2009120697A2 (enExample)
ZA (1) ZA201006988B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1721615A1 (en) 2005-05-09 2006-11-15 Komipharm International Co., Ltd. Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
PL2475362T3 (pl) * 2009-09-10 2019-09-30 Kominox, Inc. Terapia celowana w nowotworowe komórki macierzyste i raka lekoopornego
US8795738B2 (en) * 2009-11-12 2014-08-05 Board Of Regents Of The University Of Texas System Use of arsenic for cancer therapy protection
US11084811B2 (en) 2010-03-01 2021-08-10 Oncternal Therapeutics, Inc. Compounds for treatment of cancer
WO2012012305A2 (en) * 2010-07-18 2012-01-26 Niiki Pharma Inc. Combination therapy using a ruthenium complex
MX336761B (es) * 2010-08-24 2016-01-29 Univ Tennessee Res Foundation Compuestos para el tratamiento de cancer.
WO2012131487A2 (en) * 2011-03-30 2012-10-04 Kominox, Inc. Compositions and methods for the treatment of cancer
US8834938B2 (en) 2011-05-18 2014-09-16 Board Of Regents Of The University Of Texas System Use of arsenic for cancer therapy protection
WO2012155061A1 (en) * 2011-05-12 2012-11-15 Board Of Regents, University Of Texas System Use of arsenic for cancer therapy protection
KR101309844B1 (ko) 2013-03-15 2013-09-23 박상채 항암 활성 증진용 한약재 및 이의 제조방법
US20160184356A1 (en) * 2013-03-15 2016-06-30 Ke Jian Jim Liu Arsenic-based treatment of cancers and inflammatory disorders
AU2014290012B2 (en) * 2013-07-19 2020-01-16 Onyx Therapeutics, Inc. Peptide epoxyketone proteasome inhibitors in combination with PIM kinase inhibitors for treatment of cancers
AU2017368444B9 (en) 2016-12-01 2020-07-02 Eupharma Pty Ltd Arsenic compositions
CA3094115A1 (en) 2018-03-22 2019-09-26 Komipharm International Australia Pty Ltd Pharmaceutical composition comprising meta arsenite and method of manufacture
CN116236505A (zh) * 2023-03-15 2023-06-09 上海市第四人民医院 三氧化二砷在制备肺神经内分泌癌治疗药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1391206B1 (en) * 1997-10-15 2008-07-02 Polarx Biopharmaceuticals, Inc. Pharmaceutical compositions comprising arsenic trioxide for the treatment of non-Hodgkin's lymphoma
IL136051A0 (en) * 1997-11-10 2001-05-20 Sloan Kettering Inst Cancer Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
KR20020083678A (ko) * 2001-04-28 2002-11-04 주식회사 한국미생물연구소 아르세닉산나트륨 염, 소디움 메타아르세나이트 또는 이의혼합물을 함유한 항암제 조성물
ES2944907T3 (es) * 2002-04-10 2023-06-27 Komipharm Int Co Ltd Uso de meta-arsenito de sodio para el tratamiento de tumores
EP1721615A1 (en) * 2005-05-09 2006-11-15 Komipharm International Co., Ltd. Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
US8097237B2 (en) * 2005-08-23 2012-01-17 Stc.Unm Non-invasive diagnostic agents of cancer and methods of diagnosing cancer, especially leukemia and lymphoma
WO2009049258A1 (en) * 2007-10-12 2009-04-16 The Johns Hopkins University Compounds for hedgehog pathway blockade in proliferative disorders, including hematopoietic malignancies

Also Published As

Publication number Publication date
EP2268292A4 (en) 2011-05-11
LT2268292T (lt) 2018-03-26
PL2268292T3 (pl) 2018-06-29
RU2010143893A (ru) 2012-05-10
WO2009120697A2 (en) 2009-10-01
AU2009228378B2 (en) 2014-07-17
DK2268292T3 (en) 2018-03-12
EP2268292A2 (en) 2011-01-05
JP2014101387A (ja) 2014-06-05
BRPI0909164A2 (pt) 2016-06-21
MX2010010621A (es) 2011-04-05
JP2011515481A (ja) 2011-05-19
EP2268292B1 (en) 2017-12-27
HUE036609T2 (hu) 2018-07-30
SI2268292T1 (en) 2018-03-30
CA2719766A1 (en) 2009-10-01
AU2009228378A1 (en) 2009-10-01
CN102046187A (zh) 2011-05-04
ZA201006988B (en) 2012-05-30
WO2009120697A4 (en) 2010-04-15
PT2268292T (pt) 2018-02-19
CY1120536T1 (el) 2019-07-10
JP5543956B2 (ja) 2014-07-09
WO2009120697A3 (en) 2010-02-18
US20180055812A1 (en) 2018-03-01
KR20110009664A (ko) 2011-01-28
US20090246291A1 (en) 2009-10-01
KR101634138B1 (ko) 2016-06-28
CN104997808A (zh) 2015-10-28
RU2508116C2 (ru) 2014-02-27
CA2719766C (en) 2017-10-31

Similar Documents

Publication Publication Date Title
ES2649340T3 (es) Administración de fármacos activados por hipoxia y agentes antiangiogénicos para el tratamiento del cáncer
CY1125550T1 (el) Ορισμενες τριαζολοπυραζινες, συνθεσεις αυτων και μεθοδοι για τη χρηση αυτων
ES2556585T3 (es) Composiciones que comprenden sulfato de salbutamol
CL2007002994A1 (es) Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
MX2010002179A (es) Composicion para el tratamiento de enfermedades neoplasicas.
CO6531430A2 (es) Tratamiento de cáncer de antagonistas notch 1 resistentes utilizando antagonistas notch3
MX2010010726A (es) Composicion de estilizado de cabello.
CL2011001853A1 (es) Uso de una combinacion farmaceutica que comprende linagliptina y un segundo agente antidiabetico seleccionado entre biguanidas, tiazolidindionas, sulfonilureas, glinidas, entre otros, y, opcionalmente, un tercer agente antidiabetico, para tratar diabetes mellitus tipo 2 y complicaciones de la diabetes, entre otras.
CL2008002224A1 (es) Composicion farmaceutica que comprende a) un compuesto seleccionado entre paclitaxel, docetaxel, ispinesib, tiazoloquinolina, entre otro, y b) compuestos inhibidores de aurora quinasa seleccionados entre derivados de imidazopirazina; uso de combinacion y de la composicion para tratar el cancer.
CL2008002982A1 (es) Compuestos derivados de 4,5-difenil-imidazol sustituidos por heterociclos, inhibidores mdm2; composicion farmaceutica que los comprende; proceso de preparacion de los compuestos; y uso en el tratamiento del cancer de mama, colon, pulmon o prostata.
CL2008001633A1 (es) Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer.
CL2008001076A1 (es) Compuestos derivados de sulfonamida; composicion farmaceutica; y uso en el tratamiento del cancer.
CL2008002369A1 (es) Compuestos derivados de piridin-3-il-oxipiridin-2-il-amino, inhibidores de alk5; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del cancer.
CL2011000504A1 (es) Compuestos derivados de piridin-4-il-tiazol-2il-amida 2-amida-pirrolidin-1,2-dicarboxilico, inhibidores de quinasa de fosfatidil-inositol-3; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de un medicamento para el tratamiento del cancer.
CL2007002018A1 (es) Compuestos derivados de isoxazolinas sustituidas; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto para el tratamiento de una enfermedad causada por un aumento en la proliferacion celular.
MX2013004832A (es) Compuestos y composiciones para el tratamiento del cancer.
CL2007000161A1 (es) Compuestos derivados de 2,4-dioxoimidazolidina sustituida, inhibidores de proteinas cinasas; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer.
UY30759A1 (es) Compuestos quimicos
RU2012111235A (ru) Комбинированная терапия композициями наночастиц таксана и ингибиторами хэджхог
JP2008535927A5 (enExample)
ECSP055618A (es) Terapia de combinacion para enfermedades hiperproliferativas
CL2008003873A1 (es) Compuestos derivados de benzofuropirimidinona sustituidos, inhibidores de proteinas quinasas; composicion farmaceutica que comprende a uno de los compuestos; metodo para inhibir in vitro proteinas quinasa (pim, cdc7,ck2); y uso de los compuestos en la preparacion de medicamentos para el tratamiento del cancer
CO6390097A2 (es) Formulaciones para el cuidado oral que incrementa la cantidad de zinc soluble
CO6321225A2 (es) Particulas portadoras sólidas para mejorar la procesabilidad de un agente farmacéutico
CO6290654A2 (es) Derivados de salinosporamida como inhibidores de proteasoma